The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...
Merck (NYSE: MRK) rose after six straight sessions of losses, with shares up 2.17% at $117.97 on Friday afternoon. Over the prior six sessions, the stock had fallen 6.27%, underperforming a 3.81% gain ...
PM UTC It will lose patent exclusivity within the next two years, but Merck has earned approval for a new, subcutaneous ...
Zacks Investment Research on MSN
Merck (MRK) stock sinks as market gains: Here's why
Merck (MRK) closed at $120.15 in the latest trading session, marking a -1.05% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.02%. Elsewhere, the Dow saw an ...
On April 13, UBS analyst Michael Yee lifted the firm’s price recommendation on Merck & Co., Inc. (NYSE:MRK) to $145 from $130 ...
U.S. FDA accepts and grants Priority Review for the Biologics License Application for ifinatamab deruxtecan. The application ...
Despite the president’s plan to lower prescription medicine costs, the price of many of the most expensive drugs — including ...
Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that ...
Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for ...
Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results